3,4-Methylenedioxymethamphetamine (MDMA; ecstasy) is being investigated in MDMA-assisted psychotherapy. The present study characterized the safety pharmacology of single-dose administrations of MDMA (75 or 125 mg) using data from nine double-blind, placebo-controlled, crossover studies performed in the same laboratory in a total of 166 healthy subjects. The duration of the subjective effects was 4.2 ± 1.3 h (range: 1.4–8.2 h). The 125 mg dose of MDMA produced greater ‘good drug effect’ ratings than 75 mg. MDMA produced moderate and transient ‘bad drug effect’ ratings, which were greater in women than in men. MDMA increased systolic blood pressure to >160 mmHg, heart rate >100 beats/min, and body temperature >38°C in 33%, 29% and 19% of the subjects, respectively. These proportions of subjects with hypertension (>160 mmHg), tachycardia, and body temperature >38°C were all significantly greater after 125 mg MDMA compared with the 75 mg dose. Acute and subacute adverse effects of MDMA as assessed by the List of Complaints were dose-dependent and more frequent in females. MDMA did not affect liver or kidney function at EOS 29 ± 22 days after use. No serious adverse events occurred. In conclusion, MDMA produced predominantly acute positive subjective drug effects. Bad subjective drug effects and other adverse effects were significantly more common in women. MDMA administration was overall safe in physically and psychiatrically healthy subjects and in a medical setting. However, the risks of MDMA are likely higher in patients with cardiovascular disease and remain to be investigated in patients with psychiatric disorders.
BaggottMJCoyleJRSiegristJD. (2016) Effects of 3,4-methylenedioxymethamphetamine on socioemotional feelings, authenticity, and autobiographical disclosure in healthy volunteers in a controlled setting. J Psychopharmacol30: 378–387.
4.
BediGHymanDde WitH (2010) Is ecstasy an “empathogen”? Effects of ± 3,4-methylenedioxymethamphetamine on prosocial feelings and identification of emotional states in others. Biol Psychiatry68: 1134–1140.
5.
Ben-AbrahamRSzoldORudickV. (2003) ‘Ecstasy’ intoxication: Life-threatening manifestations and resuscitative measures in the intensive care setting. Eur J Emerg Med10: 309–313.
6.
BershadAKKirkpatrickMGSeidenJA. (2015) Effects of acute doses of prosocial drugs methamphetamine and alcohol on plasma oxytocin levels. J Clin Psychopharmacol35: 308–312.
7.
BershadAKMillerMABaggottMJ. (2016) The effects of MDMA on socio-emotional processing: Does MDMA differ from other stimulants?J Psychopharmacol30: 1248–1258.
8.
BrauerLHAmbreJDe WitH (1996) Acute tolerance to subjective but not cardiovascular effects of d-amphetamine in normal, healthy men. J Clin Psychopharmacol16: 72–76.
9.
BruntTMKoeterMWNiesinkRJ. (2012) Linking the pharmacological content of ecstasy tablets to the subjective experiences of drug users. Psychopharmacology (Berl)220: 751–762.
10.
Carhart-HarrisRLWallMBErritzoeD. (2014) The effect of acutely administered MDMA on subjective and BOLD-fMRI responses to favourite and worst autobiographical memories. Int J Neuropsychopharmacol17: 527–540.
11.
ChildsEBershadAKde WitH (2016) Effects of d-amphetamine upon psychosocial stress responses. J Psychopharmacol30: 608–615.
12.
DaftersRI (1995) Hyperthermia following MDMA administration in rats: Effects of ambient temperature, water consumption, and chronic dosing. Physiol Behav58: 877–882.
13.
de la TorreRFarreMRosetPN. (2000) Pharmacology of MDMA in humans. Ann N Y Acad Sci914: 225–237.
14.
de Sousa Fernandes PernaEBTheunissenELKuypersKP. (2014) Memory and mood during MDMA intoxication, with and without memantine pretreatment. Neuropharmacology87: 198–205.
15.
DoblinRGreerGHollandJ. (2014) A reconsideration and response to Parrott AC (2013) “Human psychobiology of MDMA or ‘Ecstasy’: An overview of 25 years of empirical research”. Hum Psychopharmacol29: 105–108.
16.
DolderPCSchmidYHaschkeM. (2015) Pharmacokinetics and concentration-effect relationship of oral LSD in humans. Int J Neuropsychopharmacol19: pyv072.
17.
DolderPCSchmidYMuellerF. (2016) LSD acutely impairs fear recognition and enhances emotional empathy and sociality. Neuropsychopharmacology41: 2638–2646.
18.
DumontGJVerkesRJ (2006) A review of acute effects of 3,4-methylenedioxymethamphetamine in healthy volunteers. J Psychopharmacol20: 176–187.
19.
DumontGJKramersCSweepFC. (2008) Ethanol co-administration moderates 3,4-methylenedioxymethamphetamine effects on human physiology. J Psychopharmacol24: 165–174.
20.
DumontGJKramersCSweepFC. (2009) Cannabis coadministration potentiates the effects of “ecstasy” on heart rate and temperature in humans. Clin Pharmacol Ther86: 160–166.
21.
EllisAJWendonJAPortmannB. (1996) Acute liver damage and ecstasy ingestion. Gut38: 454–458.
22.
FarreMAbanadesSRosetPN. (2007) Pharmacological interaction between 3,4-methylenedioxymethamphetamine (ecstasy) and paroxetine: Pharmacological effects and pharmacokinetics. J Pharmacol Exp Ther323: 954–962.
23.
FarreMde la TorreRMathunaBO. (2004) Repeated doses administration of MDMA in humans: Pharmacological effects and pharmacokinetics. Psychopharmacology (Berl)173: 364–375.
24.
FarreMTomilleroAPerez-ManaC. (2015) Human pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) after repeated doses taken 4h apart. Eur Neuropsychopharmacol25: 1637–1649.
25.
FreedmanRRJohansonCETancerME (2005) Thermoregulatory effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology (Berl)183: 248–256.
26.
GasserPHolsteinDMichelY. (2014) Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. J Nerv Ment Dis202: 513–520.
27.
GreerGTolbertR (1986) Subjective reports of the effects of MDMA in a clinical setting. J Psychoactive Drugs18: 319–327.
28.
GrunauBEWiensMOBrubacherJR (2010) Dantrolene in the treatment of MDMA-related hyperpyrexia: A systematic review. Canadian J Emerg Med12: 435–442.
29.
HalpernPMoskovichJAvrahamiB. (2011) Morbidity associated with MDMA (ecstasy) abuse: A survey of emergency department admissions. Hum Exp Toxicol30: 259–266.
30.
HartungTKSchofieldEShortAI. (2002) Hyponatraemic states following 3,4-methylenedioxymethamphetamine (MDMA, ‘ecstasy’) ingestion. Quart J Med95: 431–437.
31.
HaslerFStuderusELindnerK. (2009) Investigation of serotonin-1A receptor function in the human psychopharmacology of MDMA. J Psychopharmacol23: 923–935.
32.
HenryJAJeffreysKJDawlingS (1992) Toxicity and deaths from 3,4-methylenedioxymethamphetamine (“ecstasy”). Lancet340: 384–387.
33.
HysekCMLiechtiME (2012) Effects of MDMA alone and after pretreatment with reboxetine, duloxetine, clonidine, carvedilol, and doxazosin on pupillary light reflex. Psychopharmacology (Berl)224: 363–376.
34.
HysekCMBruggerRSimmlerLD. (2012a) Effects of the alpha2-adrenergic agonist clonidine on the pharmacodynamics and pharmacokinetics of 3,4-methylenedioxymethamphetamine in healthy volunteers. J Pharmacol Exp Ther340: 286–294.
35.
HysekCMDomesGLiechtiME (2012b) MDMA enhances “mind reading” of positive emotions and impairs “mind reading” of negative emotions. Psychopharmacology (Berl)222: 293–302.
36.
HysekCMFinkAESimmlerLD. (2013) Alpha-adrenergic receptors contribute to the acute effects of MDMA in humans. J Clin Psychopharmacol33: 658–666.
37.
HysekCMSchmidYRickliA. (2012c) Carvedilol inhibits the cardiostimulant and thermogenic effects of MDMA in humans. Br J Pharmacol166: 2277–2288.
HysekCMSimmlerLDIneichenM. (2011) The norepinephrine transporter inhibitor reboxetine reduces stimulant effects of MDMA (“ecstasy”) in humans. Clin Pharmacol Ther90: 246–255.
40.
HysekCMSimmlerLDNicolaV. (2012d) Duloxetine inhibits effects of MDMA (“ecstasy”) in vitro and in humans in a randomized placebo-controlled laboratory study. PLoS One7: e36476.
41.
HysekCMSimmlerLDSchillingerN. (2014b) Pharmacokinetic and pharmacodynamic effects of methylphenidate and MDMA administered alone and in combination. Int J Neuropsychopharmacol17: 371–381.
42.
Kamilar-BrittPBediG (2015) The prosocial effects of 3,4-methylenedioxymethamphetamine (MDMA): Controlled studies in humans and laboratory animals. Neurosci Biobehav Rev57: 433–446.
43.
KirkpatrickMGBaggottMJMendelsonJE. (2014a) MDMA effects consistent across laboratories. Psychopharmacology (Berl)231: 3899–3905.
44.
KirkpatrickMGGundersonEWPerezAY. (2012) A direct comparison of the behavioral and physiological effects of methamphetamine and 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology (Berl)219: 109–122.
45.
KirkpatrickMGLeeRWardleMC. (2014b) Effects of MDMA and intranasal oxytocin on social and emotional processing. Neuropsychopharmacology39: 1654–1663.
46.
KolbrichEAGoodwinRSGorelickDA. (2008a) Physiological and subjective responses to controlled oral 3,4-methylenedioxymethamphetamine administration. J Clin Psychopharmacol28: 432–440.
47.
KolbrichEAGoodwinRSGorelickDA. (2008b) Plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine after controlled oral administration to young adults. Ther Drug Monit30: 320–332.
48.
KupferschmidtK (2014) Can ecstasy treat the agony of PTSD?Science345: 22–23.
49.
KuypersKPdelaTorreRFarreM. (2014) No evidence that MDMA-induced enhancement of emotional empathy is related to peripheral oxytocin levels or 5-HT1a receptor activation. PLoS One9: e100719.
50.
KuypersKPTheunissenELvan WelJH. (2016) Verbal memory impairment in polydrug ecstasy users: A clinical perspective. PLoS One11: e0149438.
51.
LiechtiME (2014) Effects of MDMA on body temperature in humans. Temperature1: 179–187.
52.
LiechtiMEGammaAVollenweiderFX (2001) Gender differences in the subjective effects of MDMA. Psychopharmacology (Berl)154(2): 161–168.
53.
LiechtiMEKunzIKupferschmidtH (2005) Acute medical problems due to Ecstasy use: Case-series of emergency department visits. Swiss Med Wkly135: 652–657.
54.
LitjensRPBruntTMAlderliefsteGJ. (2014) Hallucinogen persisting perception disorder and the serotonergic system: A comprehensive review including new MDMA-related clinical cases. Eur Neuropsychopharmacol24: 1309–1323.
55.
MaharajRPingitoreAMenonK. (2015) Images of the month: MDMA-induced acute liver failure and transient abdominal pneumatosis. Am J Gastroenterol110: 963.
56.
MAPS (2016) MDMA Investigator’s Brochure. Multidisciplinary Association for Psychedelic Studies (MAPS). Available at: http://www.maps.org/research/mdma (accessed 10 November 2016).
57.
MartinWRSloanJWSapiraJD. (1971) Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin Pharmacol Ther12: 245–258.
58.
MithoeferMCGrobCSBrewertonTD (2016) Novel psychopharmacological therapies for psychiatric disorders: Psilocybin and MDMA. Lancet Psychiatry3: 481–488.
59.
MithoeferMCWagnerMTMithoeferAT. (2010) The safety and efficacy of ±3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: The first randomized controlled pilot study. J Psychopharmacol25: 439–452.
60.
MuellerFLenzCSteinerM. (2016) Neuroimaging in moderate MDMA use: A systematic review. Neurosci Biobehav Rev62: 21–34.
61.
OehenPTraberRWidmerV. (2013) A randomized, controlled pilot study of MDMA (±3,4-methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic post-traumatic stress disorder (PTSD). J Psychopharmacol27: 40–52.
62.
Pardo-LozanoRFarreMYubero-LahozS. (2012) Clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”): The influence of gender and genetics (CYP2D6, COMT, 5-HTT). PLoS One7: e47599.
63.
ParrottAC (2007) The psychotherapeutic potential of MDMA (3,4-methylenedioxymethamphetamine): An evidence-based review. Psychopharmacology (Berl)191: 181–193.
64.
ParrottAC (2013a) Human psychobiology of MDMA or ‘Ecstasy’: An overview of 25 years of empirical research. Hum Psychopharmacol28: 289–307.
65.
ParrottAC (2013b) MDMA, serotonergic neurotoxicity, and the diverse functional deficits of recreational ‘Ecstasy’ users. Neurosci Biobehav Rev37: 1466–1484.
66.
ParrottAC (2014) The potential dangers of using MDMA for psychotherapy. J Psychoactive Drugs46: 37–43.
67.
ParrottACGibbsAScholeyAB. (2011) MDMA and methamphetamine: Some paradoxical negative and positive mood changes in an acute dose laboratory study. Psychopharmacology (Berl)215: 527–536.
68.
PeiroAMFarreMRosetPN. (2013) Human pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) after repeated doses taken 2 h apart. Psychopharmacology (Berl)225: 883–893.
69.
RenemanLBooijJde BruinK. (2001) Effects of dose, sex, and long-term abstention from use on toxic effects of MDMA (ecstasy) on brain serotonin neurons. Lancet358: 1864–1869.
70.
RogersGElstonJGarsideR. (2009) The harmful health effects of recreational ecstasy: A systematic review of observational evidence. Health Technol Assess13: iii–iv, ix–xii, 1–315.
71.
RosensonJSmollinCSporerKA. (2007) Patterns of ecstasy-associated hyponatremia in California. Ann Emerg Med49: 164–171.
72.
RothmanRBBaumannMHDerschCM. (2001) Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse39: 32–41.
73.
SchmidYEnzlerFGasserP. (2015a) Acute effects of lysergic acid diethylamide in healthy subjects. Biol Psychiatry78: 544–553.
74.
SchmidYHysekCMSimmlerLD. (2014) Differential effects of MDMA and methylphenidate on social cognition. J Psychopharmacol28: 847–856.
75.
SchmidYRickliASchaffnerA. (2015b) Interactions between bupropion and 3,4-methylenedioxymethamphetamine in healthy subjects. J Pharmacol Exp Ther353: 102–111.
76.
SchmidYVizeliPHysekCM. (2016) CYP2D6 function moderates the pharmacokinetics and pharmacodynamics of MDMA in a controlled study in healthy subjects. Pharmacogenet Genom26: 397–401.
77.
SessaB (2016) MDMA and PTSD treatment: “PTSD: From novel pathophysiology to innovative therapeutics”. Neurosci Lett. Epub ahead of print 6 July 2016. DOI: 10.1016/j.neulet.2016.07.004.
78.
SessaBNuttD (2015) Making a medicine out of MDMA. Br J Psychiatry206: 4–6.
79.
SimmlerLBuserTDonzelliM. (2013) Pharmacological characterization of designer cathinones in vitro. Br J Pharmacol168(2): 458–470.
80.
SimmlerLDHysekCMLiechtiME (2011) Sex differences in the effects of MDMA (ecstasy) on plasma copeptin in healthy subjects. J Clin Endocrinol Metab96: 2844–2850.
81.
TancerMJohansonCE (2003) Reinforcing, subjective, and physiological effects of MDMA in humans: a comparison with d-amphetamine and mCPP. Drug Alcohol Depend72: 33–44.
82.
Van WelJHKuypersKPTheunissenEL. (2012) Effects of acute MDMA intoxication on mood and impulsivity: role of the 5-HT2 and 5-HT1 receptors. PLoS One7: e40187.
83.
VerheydenSLHadfieldJCalinT. (2002) Sub-acute effects of MDMA (+/-3,4-methylenedioxymethamphetamine, “ecstasy”) on mood: Evidence of gender differences. Psychopharmacology (Berl)161: 23–31.
84.
VizeliPSchmidYPrestinK. (2017) Pharmacogenetics of ecstasy: CYP1A2, CYP2C19, and CYP2B6 polymorphisms moderate pharmacokinetics of MDMA in healthy subjects. Eur Neuropharmacol. Epup ahead of print 20 January 2017. DOI:10.1016/j.euroneuro.2017.01.008.
85.
VollenweiderFXGammaALiechtiME. (1998) Psychological and cardiovascular effects and short-term sequelae of MDMA (“ecstasy”) in MDMA-naive healthy volunteers. Neuropsychopharmacology19: 241–251.
86.
WardleMCDe WitH (2012) Effects of amphetamine on reactivity to emotional stimuli. Psychopharmacology (Berl)220: 143–153.
87.
WardleMCGarnerMJMunafoMR. (2012) Amphetamine as a social drug: Effects of d-amphetamine on social processing and behavior. Psychopharmacology (Berl)223: 199–210.
88.
WardleMCKirkpatrickMGde WitH (2014) ‘Ecstasy’ as a social drug: MDMA preferentially affects responses to emotional stimuli with social content. Soc Cogn Affect Neurosci9: 1076–1081.
89.
WoodDMGiraudonIMounteneyJ. (2016) Hospital Emergency Presentations and Acute Drug Toxicity in Europe: Update from the Euro-DEN Plus Research Group and the EMCDDA. Lisbon, Portugal: European Monitoring Center for Drugs and Drug Addiction.
90.
ZerssenDV (1976) Die Beschwerden-Liste. Münchener Informationssystem. München: Psychis.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
